The influence of prostate volume in prostate health index performance in patients with total PSA lower than 10μg/L

Clinica Chimica Acta

Volumn 436, Issue , 2014, Pages 303-307

  Filella, Xavier ^a   Foj, Laura ^a   Alcover, Joan ^a   Augé, Josep Maria ^a   Molina, Rafael ^a   Jiménez, Wladimiro ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

P2PSA; Prostate cancer; Prostate health index; Prostate volume; PSA

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; PROSTATE-SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX MEASUREMENT; PROSTATE VOLUME; ANATOMY AND HISTOLOGY; BLOOD; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN SIZE; PATHOLOGY; PROSTATE; PROSTATIC NEOPLASMS;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84904044333     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.019     Document Type: Article

References (16)

1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
2. Filella X., Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013, 51:729-739.
3. Stephan C., Vincendeau S., Houlgatte A., Cammann H., Jung K., Semjonow A. Multicenter evaluation of [-2] proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 2013, 59:306-314.
4. Lazzeri M., Haese A., de la Taille A., Palou Redorta J., McNicholas T., Lughezzani G., et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10ng/ml: a multicentric European study. Eur Urol 2013, 63:986-994.
5. Lughezzani G., Lazzeri M., Larcher A., Lista G., Scattoni V., Cestari A., et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. J Urol 2012, 188:1144-1150.
6. Sturgeon C.M., Duffy M.J., Stenman U.H., Lilja H., Brünner N., Chan D.W., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54:e11-e79.
7. Semjonow A., Kopke T., Eltze E., Pepping-Schefers B., Burgel H., Darte C. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010, 43:926-928.
8. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
9. Vickers A.J., Elkin E.B. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006, 26:565-574.
10. Chou R., Croswell J.M., Dana T., Bougatsos C., Blazina I., Fu R., et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155:762-771.
11. Filella X., Foj L., Augé J.M., Molina R., Alcover J. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clin Chem Lab Med Apr 2 2014, [pii:/j/cclm.ahead-of-print/cclm-2014-0027/cclm-2014-0027.xml]. 10.1515/cclm-2014-0027.
12. Catalona W.J., Partin A.W., Sanda M.G., Wei J.T., Klee G.G., Bangma C.H., et al. A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0ng/ml prostate specific antigen range. J Urol 2011, 185:1650-1655.
13. Guazzoni G., Nava L., Lazzeri M., Scattoni V., Lughezzani G., Maccagnano C., et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011, 60:214-222.
14. Mikolajczyk S.D., Song Y., Wong J.R., Matson R.S., Rittenhouse H.G. Are multiple markers the future of prostate cancer diagnostics?. Clin Biochem 2004, 37:519-528.
15. Sokoll L.J., Sanda M.G., Feng Z., Kagan J., Mizrahi I.A., Broyles D.L., et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 2010, 19:1193-1200.
16. Stephan C., Kahrs A.M., Cammann H., Lein M., Schrader M., Deger S., et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009, 69:198-207.